Woodlands, Texas-based VGXI Inc., a contract manufacturing organization (CMO) and provider of plasmid DNA manufacturing and development services for DNA vaccine and gene therapy research, announced they have entered into a partnership and licensing agreement with a commercial scale manufacturer for GMP plasmid production.
This announcement was made just a month after the company announced they would be expanding their Woodlands based facility by 3,000 square feet to include a small-scale cGMP (compliant with the U.S. Food and Drug Administration’s current Good Manufacturing Practice regulations) production plant.
The new agreement states that the partnering company will utilize VGXI’s exclusive plasmid manufacturing and purification technologies to produce DNA-based pharmaceuticals at a commercial-scale level. The technology transfer is currently being undertaken, and a large scale GMP plasmid production will be available after the completion of the transfer.
In a press release, VGXI’s CEO, Young Park JD, MBA stated, “We are extremely pleased to be able to offer this new capability to all of our current and prospective customers. Several clients have expressed a need for increased production volumes, and this partnership will allow commercial scalability until VGXI has established its own large-scale manufacturing facility.”
This partnership will be ideally suited to meet the increasing demand for DNA pharmaceuticals. Already experienced in supplying cGMP plasmid products for clients worldwide, VGXI has cultivated a manufacturing expertise in delivering quality CMO services and DNA products to its current clients.
The strategic partnership announced they will provide the biopharmaceutical industry with a unified DNA manufacturing solution and facilitate further development of genetic vaccines and bio-pharmaceutical therapeutics. This will allow VGXI to move closer towards meeting its mission of revolutionizing the global pharmaceutical community by producing the highest quality DNA products and services available.
VGXI is a wholly owned subsidiary of GeneOne Life Science, Inc, a pharmaceutical company engaged in the manufacture of woven and knitted interlinings and bio-pharmaceuticals. Its products and services include DNA vaccine, bio-pharmaceuticals CMO business, real estate marketing and leasing services. The company was founded on in 1976 and is headquartered in Seoul, South Korea.